In breast, esophageal, and lung cancers, Par3 seems to act as a tumor suppressor [22, 23, 25], whilst in clear-cell renal carcinoma, Par3 overexpression is associated with poor prognosis [27, 28]. Here, PARD3 is linked to neoplasm.